Indeed, although in HER2-positive breast cancer almost all patients deserve chemotherapy as per standard of care, a reliable prognostic estimation has several implications, from the planning of premenopausal patients’ reproductive life (e.g. affecting the choice of having or not a pregnancy later on23), to a therapeutic perspective (adoption of escalation or de-escalation treatment strategies, including type of chemotherapy to be administered together with anti-HER2 treatment and use of extended adjuvant endocrine therapy in hormone receptor-positive disease24). The gene discussed is ERBB2; the disease is breast carcinoma.